tetano
Editor, Senior Moderator
J Med Virol
. 2023 Nov;95(11):e29225.
doi: 10.1002/jmv.29225. Superior neutralizing response after first versus second SARS-CoV-2 infection in fully vaccinated individuals
Gonzalo Rivas[SUP] 1 2 [/SUP], Nuria Labiod[SUP] 1 [/SUP], Joanna Luczkowiak[SUP] 1 [/SUP], Fátima Lasala[SUP] 1 [/SUP], Marta Rolo[SUP] 2 [/SUP], Mikel Mancheño-Losa[SUP] 3 [/SUP], David Rial-Crestelo[SUP] 3 4 [/SUP], Jaime Lora-Tamayo[SUP] 3 [/SUP], Alfredo Pérez-Rivilla[SUP] 2 [/SUP], María Dolores Folgueira[SUP] 1 2 5 [/SUP], Rafael Delgado[SUP] 1 2 4 5 [/SUP]
Affiliations
Currently, the majority of the population has been vaccinated against COVID-19 and/or has experienced SARS-CoV-2 infection either before or after vaccination. The immunological response to repeated episodes of infections is not completely clear. We measured SARS-CoV-2 specific neutralization titers by a pseudovirus assay after BA.1 infection and RBD-specific immunoglobulin G (IgG), immunoglobulin A (IgA), and immunoglobulin M (IgM) in a cohort of COVID-19 uninfected and triple vaccinated individuals (breakthrough infection group, BTI) as compared with those previously infected by SARS-CoV-2 (reinfection group, REI) who underwent identical vaccination schedule. SARS-CoV-2 specific neutralizing response after BA.1 infection was significantly higher in the BTI group as compared with the REI. Furthermore, neutralization titers in REI were not significant different from convalescent non reinfected controls. RBD-specific IgG and IgA, but not IgM, were also significantly higher in BTI as compared with REI. Our results show that the first episode of SARS-CoV-2 infection induces a significant increase in neutralizing titers in triple vaccinated individuals and that previous SARS-CoV-2 infection compromise significantly the neutralization response induced by reinfection, even by divergent SARS-CoV-2 variants and at least up to 2 years postinfection, suggesting a fundamental limitation in inducing effective booster through the intranasal route in previously infected individuals.
Keywords: SARS coronavirus; coronavirus; humoral immunity; neutralization; reinfection; vaccines/vaccine strains.
. 2023 Nov;95(11):e29225.
doi: 10.1002/jmv.29225. Superior neutralizing response after first versus second SARS-CoV-2 infection in fully vaccinated individuals
Gonzalo Rivas[SUP] 1 2 [/SUP], Nuria Labiod[SUP] 1 [/SUP], Joanna Luczkowiak[SUP] 1 [/SUP], Fátima Lasala[SUP] 1 [/SUP], Marta Rolo[SUP] 2 [/SUP], Mikel Mancheño-Losa[SUP] 3 [/SUP], David Rial-Crestelo[SUP] 3 4 [/SUP], Jaime Lora-Tamayo[SUP] 3 [/SUP], Alfredo Pérez-Rivilla[SUP] 2 [/SUP], María Dolores Folgueira[SUP] 1 2 5 [/SUP], Rafael Delgado[SUP] 1 2 4 5 [/SUP]
Affiliations
- PMID: 37971751
- DOI: 10.1002/jmv.29225
Currently, the majority of the population has been vaccinated against COVID-19 and/or has experienced SARS-CoV-2 infection either before or after vaccination. The immunological response to repeated episodes of infections is not completely clear. We measured SARS-CoV-2 specific neutralization titers by a pseudovirus assay after BA.1 infection and RBD-specific immunoglobulin G (IgG), immunoglobulin A (IgA), and immunoglobulin M (IgM) in a cohort of COVID-19 uninfected and triple vaccinated individuals (breakthrough infection group, BTI) as compared with those previously infected by SARS-CoV-2 (reinfection group, REI) who underwent identical vaccination schedule. SARS-CoV-2 specific neutralizing response after BA.1 infection was significantly higher in the BTI group as compared with the REI. Furthermore, neutralization titers in REI were not significant different from convalescent non reinfected controls. RBD-specific IgG and IgA, but not IgM, were also significantly higher in BTI as compared with REI. Our results show that the first episode of SARS-CoV-2 infection induces a significant increase in neutralizing titers in triple vaccinated individuals and that previous SARS-CoV-2 infection compromise significantly the neutralization response induced by reinfection, even by divergent SARS-CoV-2 variants and at least up to 2 years postinfection, suggesting a fundamental limitation in inducing effective booster through the intranasal route in previously infected individuals.
Keywords: SARS coronavirus; coronavirus; humoral immunity; neutralization; reinfection; vaccines/vaccine strains.